The United States Patent and Trademark Office (USPTO) has issued patent US12582809B2 to BT Bidco, Inc. This patent covers methods and compositions for treating diseases of the gastrointestinal tract utilizing a PDE4 inhibitor. The patent application was filed on January 24, 2019, and includes 20 claims.

This patent grant is primarily an intellectual property matter and does not impose new regulatory obligations on pharmaceutical companies or healthcare providers. However, it may affect market exclusivity and competitive landscapes for treatments related to gastrointestinal diseases and PDE4 inhibitors. Companies operating in this therapeutic area should be aware of the patent's existence and scope.